Table 1.
Demographics and clinical characteristics of patients with CRC who started 1L FOLFOX plus an anti-EGFR antibody, followed by 2L irinotecan-based chemotherapy plus any antiangiogenic drug
| Variable | Start of 1L therapy (N = 1163) | Start of 2L therapy (N = 1163) | Start of 2L therapy | ||
|---|---|---|---|---|---|
| Bevacizumab (n = 736) | Ramucirumab (n = 314) | Aflibercept beta (n = 113) | |||
| Number of hospital beds | |||||
| < 200 beds | 45 (3.9) | 30 (4.1) | 13 (4.1) | 2 (1.8) | |
| 200–499 beds | 641 (55.1) | 394 (53.5) | 192 (61.1) | 55 (48.7) | |
| ≥ 500 beds | 477 (41.0) | 312 (42.4) | 109 (34.7) | 56 (49.6) | |
| Designated cancer hospital | 907 (78.0) | 563 (76.5) | 246 (78.3) | 98 (86.7) | |
| Demographics/disease characteristics | |||||
| Sex: male | 789 (67.8) | 492 (66.8) | 216 (68.8) | 81 (71.7) | |
| Age, years, mean (SD) | 64.2 (10.5) | 65.0 (10.5)a | 65.1 (10.4)a | 64.7 (10.3)a | 64.6 (11.2)a |
| BMI, kg/m2, mean (SD)b | 22.1 (3.4)c | 21.9 (3.7)d | 22.1 (3.8)e | 21.7 (3.2)f | 21.4 (3.8)g |
| BMI ≤ 18.5 kg/m2 b | 124 (12.6)c | 97 (18.0)d | 55 (15.7)e | 29 (21.3)f | 13 (25.0)g |
| ADL – independentb | 906 (93.3)h | 474 (89.3)i | 303 (88.6)j | 124 (91.9)k | 47 (87.0)l |
| ADL – dependentb | 65 (6.7)h | 57 (10.7)i | 39 (11.4)j | 11 (8.1)k | 7 (13.0)l |
| Left-sided CRCm | 970 (83.4) | 605 (82.2) | 269 (85.7) | 96 (85.0) | |
| Right-sided CRCm | 125 (10.7) | 81 (11.0) | 34 (10.8) | 10 (8.8) | |
| Antitumor therapies | |||||
| CRC surgery before index date | 493 (42.4) | – | 295 (40.1) | 146 (46.5) | 52 (46.0) |
| CRC conversion surgery during 1L therapy | – | 111 (9.5) | 72 (9.8) | 25 (8.0) | 14 (12.4) |
| Liver surgery during 1L therapy | – | 69 (5.9) | 36 (4.9) | 25 (8.0) | 8 (7.1) |
| Lung surgery during 1L therapy | – | 4 (0.3) | 2 (0.3) | 2 (0.6) | 0 (0) |
| Duration of 1L therapy, mean, months (SD) | – | 9.57 (6.94) | 9.48 (7.01) | 9.58 (6.92) | 10.11 (6.55) |
| Sites of metastasisb | |||||
| Liver | 688 (59.2) | 719 (61.8) | 456 (62.0) | 187 (59.6) | 76 (67.3) |
| Lung | 191 (16.4) | 237 (20.4) | 139 (18.9) | 78 (24.8) | 20 (17.7) |
| Bone | 47 (4.0) | 77 (6.6) | 51 (6.9) | 21 (6.7) | 5 (4.4) |
| Brain | 7 (0.6) | 9 (0.8) | 8 (1.1) | 0 (0) | 1 (0.9) |
| Comorbiditiesb | |||||
| Hypertension | 365 (31.4) | 446 (38.3) | 277 (37.6) | 120 (38.2) | 49 (43.4) |
| Diabetes | 286 (24.6) | 316 (27.2) | 192 (26.1) | 90 (28.7) | 34 (30.1) |
| Liver disease | 200 (17.2) | 284 (24.4) | 169 (23.0) | 83 (26.4) | 32 (28.3) |
| Renal disease | 97 (8.3) | 113 (9.7) | 63 (8.6) | 38 (12.1) | 12 (10.6) |
| Dry skin/itching | 310 (26.7) | 924 (79.4) | 581 (78.9) | 248 (79.0) | 95 (84.1) |
| Rash/acne | 77 (6.6) | 383 (33.0) | 247 (33.6) | 106 (33.8) | 30 (26.6) |
| Paronychia | 4 (0.3) | 94 (8.1) | 58 (7.9) | 28 (8.9) | 8 (7.1) |
| Neuropathy | 56 (4.8) | 227 (19.5) | 139 (18.9) | 60 (19.1) | 28 (24.8) |
All values are n (%) unless indicated otherwise
1L/2L first-line/second-line, ADL activities of daily living, BMI body mass index, CRC colorectal cancer, EGFR epidermal growth factor receptor, FOLFOX leucovorin + 5-fluorouracil + oxaliplatin, SD standard deviation
aAssessed at the start of second-line therapy
bAssessed within 60 days before the index date for first-line therapy and within 60 days before starting second-line therapy for second-line therapy
cN = 986
dN = 538
eN = 350
fN = 136
gN = 52
hN = 971
iN = 531
jN = 342
kN = 135
lN = 54
mAssessed within 60 days before the index date for first-line therapy